The biotechnology company has received clearance to enroll children and adolescents in its ongoing HG-CT-1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
The biopharmaceutical firm reports promising clinical progress in its Phase I trial for AML treatment. However, financial challenges loom with doubled losses and urgent funding needs.
The biotechnology company has signed a letter of intent with a leading Estonian cell therapy firm to advance the commercialization of its HG-CT-1 CAR-T therapy for relapsed or refractory acute myeloid leukemia.
The healthcare company has announced changes to its major shareholders.
The biotechnology company reports successful treatment of a third patient in the ongoing clinical trial of its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia.
The biotechnology company has been invited to present at the upcoming DCNY Summit, a prestigious event connecting policymakers, investors, and innovators.
The biotechnology company has announced a manufacturing partnership to advance its lead CAR-T therapy for relapsed/refractory acute myeloid leukemia.
The biotechnology company has raised £235,799 through the exercise of warrants, strengthening its balance sheet without significant dilution to shareholders.
The biotechnology company has raised £450,000 through the exercise of warrants, but at a steep 73.4% discount to the previous closing price, suggesting low market confidence.
The biotechnology company has raised £620,000 through the issue of convertible loan notes to support the ongoing clinical trial of its lead product candidate.